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The relationship between obesity and cancer screening varies by screening test, race, and gender. Most studies on cervical cancer
screening found a negative association between increasing weight and screening, and this negative association was most consistent
in white women. Recent literature on mammography reports no association with weight. However, some studies show a negative
association in white, but not black, women. In contrast, obese/overweight men reported higher rates of prostate-specific antigen
(PSA) testing. Comparison of prostate cancer screening, mammography, and Pap smears implies a gender diﬀerence in the
relationship between screening behavior and weight. In colorectal cancer (CRC) screening, the relationship between weight and
screening in men is inconsistent, while there is a trend towards lower CRC screening in higher weight women.
1. Introduction
Obesity, resulting from inactivity and poor nutrition, is
second only to tobacco use as a risk factor for cancer [1].
Obesity is associated with increased mortality for all cancers
combined, as well as for cancers of specific sites, including
colon/rectum, prostate, breast, and cervix [2, 3]. Race and
gender are also associated with poor outcomes for cancer
[4, 5]. Compared to their non-Hispanic white counterparts,
black men and women are more likely to be obese and
to have a higher cancer mortality rate [6–8]. Numerous
studies have examined the biological pathways that link
obesity to increased cancer risk, but biological pathways are
unlikely to provide a complete explanation of the association
of obesity and increased cancer mortality. Participation in
cancer screening is an important determinant of cancer
mortality, and there may be an association between obesity
and use of some types of screening. This association seems
to vary according to race, gender, and screening test. While
numerous studies suggest that obesity constitutes an obstacle
to cancer screening, [3, 9–17] the interplay between obesity
and cancer screening is not clear.
Historically, blacks and women have been less likely to
undergo cancer screening when compared to their non-
Hispanic white or male counterparts [18–21]. Obesity
may be one reason for the disparity in screening among
race/ethnicity and gender subgroups, either because obesity
is more prevalent in these groups or because in some sub-
groups, it may have a more potent eﬀect. The relationship to
obesity and cancer screening is made complex by the fact that
cancer screening tests are very diﬀerent in terms of what is
required of an individual in order to complete screening. The
relationship between obesity and cancer screening may have
a stronger negative association in certain cancer screening
tests. For example, disparities appear more pronounced for
endoscopic screening than for fecal occult blood test (FOBT)
screening [19]. This situation may exist because endoscopic
testing is more invasive or harder to do in obese patients
relative to other screening tests. Furthermore, socioeconomic
factors such as insurance status and health care access,
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which can be confounded with race/ethnicity and gender,
may contribute to the disparity [19]. Eﬀorts to measure the
contribution of race/ethnicity and gender to variation in
screening rates should take these factors into account.
In this review, we attempt to build a more comprehensive
picture of the relationship of obesity and cancer screening by
including the variables of race/ethnicity, gender, and screen-
ing test. Here, we review the available literature examining
the interactions of race/ethnicity, gender, and obesity with
cancer screening rates. Understanding the relationship of
obesity and cancer screening relative to race/ethnicity and
gender can inform eﬀorts to identify and reduce disparities
in cancer screening.
2. Materials and Methods
We reviewed articles which presented data on the rela-
tionship of any weight measure to screening for any of
the following cancers: colon, breast, cervical, or prostate.
The MEDLINE database search focused on 1996 through
April 2011. First, we extracted 2,048 articles related to
obesity, morbid obesity, overweight and BMI. From this
group of articles we extracted those having to do with the
diagnosis or prevention of neoplasms. We included various
types of cancer screening tests (colonoscopy, sigmoidoscopy,
gastrointestinal endoscopy, fecal occult blood testing, Pap
smears, mammography, and prostate-specific antigen), as
well as the more general term “mass screening”. We further
limited the search by using terms that describe articles as
qualitative research or evaluation studies, resulting in 262
articles. Abstracts and manuscripts were used to exclude
articles which did not examine the association between
weight and cancer screening in order to obtain the final 29
articles. Studies were organized according to type of cancer
screening and stratified according to gender and race. Tables
1, 2, and 3 present the studies on breast, cervical, and prostate
cancer screening. Table 4 presents the studies of obesity and
colorectal cancer screening.
3. Results
3.1. Cervical Cancer Screening. We identified one review of
research on the relationship of obesity and cervical cancer
screening [44] and three additional articles [22–24]. Twelve
studies examined the relationship of obesity and screening
for cervical cancer, and all of these studies found an associa-
tion between increased body weight and decreased utilization
of Pap smears [12–15, 25, 27–31, 45, 46]. Of the five studies
which examined the association of obesity and cervical
cancer screening in white women, all reported a negative
association. In black women, six studies examined obesity
and cervical cancer screening. Four studies reported no
association, while two studies reported a negative association
between obesity and Pap smear use in black women. Of
note, one of these two studies [28] utilized data from the
Black Women’s Health Study which includes black women
of high socioeconomic status which may be associated with
diﬀerent screening behavior. The other outlying study was
a reanalysis of the same data set using diﬀerent covariates
and inclusion criteria [15, 25]. In summary, the data seems
to suggest a negative association between obesity and cervical
cancer screening in white women which is not present, or not
as strong in black women.
3.2. Breast Cancer Screening. We identified one review of re-
search on the relationship of obesity and breast cancer
screening [44], and five additional articles [12, 22–24, 29].
None of these 11 studies showed no negative association
between weight and mammography use in women. In the
three studies that stratified the obesity-screening relationship
according to race [16, 17, 27], in one study [17] obesity was
associated with decreased utilization of mammography in
white women and increased utilization in their black coun-
terparts. In black women, two of these three studies found a
positive association between obesity andmammography use,
while one study found no eﬀect in black women.
3.3. Prostate Cancer Screening. Four studies examined the as-
sociation between obesity and prostate cancer screening,
and all used prostate-specific antigen (PSA) testing as their
outcome. Three of the four studies indicated that obese men
were more likely to have had a PSA test [9–11] when com-
pared with their normal-weight peers. One study examined
obesity and PSA testing in a cohort of men from primary care
practices and found a consistent association with obesity and
increased PSA testing, regardless of race [10].
3.4. Colorectal Cancer Screening. Colorectal cancer (CRC) is
currently the only cancer screening recommended for both
men and women, and therefore, CRC is the only screening
in which the impact of gender and obesity can be directly
compared [47]. Sixteen studies were identified that examined
the relationship of obesity and colorectal cancer (CRC)
screening [22, 24, 32–43, 48, 49], but only six studies
stratified the obesity-cancer screening relationship by gender
[35, 36, 39, 40, 42, 43]. In men, the relationship between
obesity and CRC screening was inconsistent. In men, two
studies [36, 43], indicated that obesity was associated with
lower CRC screening rates. One study indicated that obesity
was associated with higher endoscopic CRC screening rates
in men [39], and three studies indicated no association
in men [35, 40, 42]. In three studies, fecal occult blood
testing (FOBT) was examined independently and there was
no association between FOBT use and weight in men [35,
39, 40]. In women, the relationship between obesity and
CRC screening was more consistent. In women, four studies
demonstrated a negative association between obesity and
CRC screening [36, 39, 40, 43], and one study demonstrated
higher rates of CRC screening in obese women [42], and one
study showed no association [35]. One outlying study was
a case-control study that identified cases from two tumor
registries and may have had a selection bias towards women
being more likely to screen. Four studies conducted on
women reported that on endoscopy separately and in three
of the four studies, obesity was negatively associated with
screening [39, 40, 42, 43]. Three studies specifically reported
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Table 1: Cervical cancer screening and weight status.
Study Population/data source Weight categories1 Findings
Chang et al. 2010,
[22]
Medicare and Veterans
Health Administration
(VHA)
OW and OB
There was no significant association between Pap
smears and OW or OB.
Banerjea et al. 2008,
[23]
Medical Expenditure Panel
Survey (MEPS) 2003
OW and OB
OW and OB were negatively associated with Pap smears
(OR 0.72 P < 0.01).
Mitchell et al. 2008,
[24]
Canadian Community
Health Survey, national
population-based
household survey in a
universal payor system.
OW, OBI, OBII, OBIII
OW, OBI, OBII, and OBIII were negatively associated
with Pap smears. OR 0.87 (0.81−0.94), OR 0.79
(0.72−0.88), OR 0.62 (0.54–0.71), OR 0.61 (0.53–0.72).
Ferrante et al. 2007,
[12]
NHIS 2000 OW, OBI, OBII, OBIII
OBI and OBIII were negatively associated with Pap
smears. OR 0.65 (0.44–0.97), OR 0.43 (0.27–0.70).
There was no significant association between receipt of
Pap smears and OW and OBII
Wu et al. 2006, [25] NHIS 2000 OW, OB, OBI, OBII, OBIII
OBII was positively associated with underused Pap
smears in African-American women. OR 1.93
(1.03–3.01).
There was no significant association in OW, OBI, or
OBIII in African-American women.
There was no significant association between any
weight category and Pap smears for white women.
Amy et al. 2006, [26]
Purposeful sample.
Questionnaire
administered in focus
groups formed on weight
criteria.
Other: BMI 25–35, >35–45,
>55
There was significant association between receipt of
Pap smears and BMI >55 kg/m2 (x2 = 9.98, P < 0.02).
There were no significant associations between receipt
of Pap smears and BMI >35–45 or >45–55.
Ferrante et al. 2006,
[13]
Medical chart review of
urban FM practices (mostly
black and Hispanics)
nonobese (normal and
OW), OBI, OBII, OBIII
There were no significant associations between weight
status and Pap smears.
Ostbye et al. 2005,
[27]
Health and Retirement
Study (HRS) and the Asset
and Health Dynamics
Among the Oldest Old
(AHEAD)
OW, OB, OBI, OBII, OBIII
OW, OBI, OBII, OBIII were negatively associated with
Pap smears (ORs 0.78, 0.68, 0.59, 0.50)
Wee et al. 2005, [14] 2000 NHIS data OW, OB, OBI, OBII, OBIII
OBIII was negatively associated with Pap smears in
white women only. RR 0.92 (0.83−0.99).
There were no significant associations between weight
status and Pap smears in black or Hispanic women.
Datta et al. 2005, [28]
Black Women’s Health
Study 1995, USA, mailed
questionnaire, subscribers
to Essence, Black Women’s
Professional Association
and friends/relatives of
participants.
OW and OB
OB was associated with increased rate of no Pap smear
in last 2 years (OR 1.4−1.7).
No association between OW and Pap smears in last 2
years.
Coughlin et al. 2004,
[29]
BRFSS 1999, US women
≥40 OW and OB
OB was negatively associated with Pap smear use in the
last 2 years (85.9 P < 0.05)
Wee et al. 2000, [15] NHIS 1994 OW, OB, OBI, OBII, OBIII
OW, OBI, OBII, and OBIII were negatively associated
with Pap smears in white women: 3.4% (−6.4% to
−0.5%), −9.4% (−13.5% to −5.2%), −8.3% (−14.2%
to −2.3%), −8.8% (−16.9% to −0.7%).
There was no association between weight status and
receipt of Pap smears in black women.
1Predictors: OW: Overweight, OB: Obese, OBI: Obese I, OBII: Obese II, OBIII: Obese III.
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Table 2: Mammography use and weight status.
Study Population/data Source Weight categories1 Findings
Chang et al.
2010, [22]
National Medicare claims
data (Medicare), Veterans
Health Administration data
(VHA)
OW and OB
OW in Medicare beneficiaries was positively associated
with mammography in OR = 1.13 P = .02, but not in
VHA data.
There was no significant association of mammography
in OB (VHA or Medicare) or OW (VHA).
Banerjea et al.
2008,[23]
Medical Expenditure Panel
Survey (MEPS) 2003
OW and OB
There were no significant associations between
mammography use and OB or OW.
Mitchell et al.
2008, [24]
Canadian Community
Health Survey
OW, OB, OBI, OBII, OBIII
There were no significant associations between
mammography use and OW, OB (including OBI, OBII,
OBIII).
Ferrante et al.
2007, [12]
National Health Interview
Survey (NHIS) 2000
OB, OW, OBI, OBII, OBIII
OBIII was negatively associated with mammography.
(62.3% P = 0.0084).
There were no associations between mammography
and weight status in OW, OBI, or OBII women.
Amy et al. 2006,
[26]
Purposeful sample,
face-to-face questionnaire
in focus groups formed
according to weight status
BMI 25–35, >35–45, >55
There were no significant associations between
mammogram use and increasing BMI category.
Ferrante et al.
2006, [13]
Medical chart review,
urban FM practices, mostly
black and Hispanic
OBI, OBII, OBIII,
nonobese (normal and
overweight collapsed)
There was no significant association between
mammography use and weight status.
Zhu et al. 2006,
[16]
NHIS 2000 OW, OBI, OBII, OBIII
There was no significant association between weight
status and mammography in white or black women.
Ostbye et al.
2005, [27]
Health and Retirement
Study (HRS) and the Asset
and Health Dynamics
Among the Oldest Old
(AHEAD)
OW and OB
OBI, OBII, and OBIII were negatively associated with
mammogram use (OR 0.73, 0.69, 0.59, resp.).
There were no significant associations between
mammography use and OW.
Coughlin et al.
2004, [29]
Behaviorial Risk Factor
Surveillance Survey
(BRFSS) 1999
OW and OB
OB was negatively associated with mammography use.
74.6% P < 0.001.
Wee et al. 2004,
[17]
NHIS 1998 OW, OBI, OBII, OBIII
OBII was negatively associated with mammography in
white women. OR 0.83 (0.68–0.96).
OW and OBII were positively associated with
mammography in black women. OR 1.19 (1.01–1.32),
OR 1.37 (1.13–1.50).
There were no other significant associations.
Wee et al. 2000,
[15]
NHIS 1994 OW, OB, OBI, OBII, OBIII
There was no association of weight status and
mammography in white or black women.
Fontaine et al.
2001, [30]
National Data 1998 OW, OBI, OBII, OBIII
OW and OBIII were positively associated with
mammography use.
There were no significant associations between OBI,
OBII, and mammography use.
Fontaine et al.
1998, [31]
National Data Set (>80%
white) 1992
OW, OB
There was no significant association between weight
status and mammography use.
1Predictors: OW: Overweight, OB: Obese (unless otherwise specified, includes OBI, OBII, OBIII), OBI: Obese I, OBII: Obese II, OBIII: Obese III.
FOBT use in women: one indicated a negative association
between obesity and screening, while the other two indicated
no association between obesity and FOBT use in women
[35, 39, 40].These studies suggest that body weight may have
a diﬀerent impact on the likelihood of undergoing CRC
screening in men and women. In women, the majority of the
literature suggests a negative association between obesity and
CRC screening, whereas in men there is little consistency in
the association of obesity and CRC screening.
While many studies examine the relationship of obesity
to cancer screening, we identified only two that explored
the impact of race and obesity on CRC screening. In the
New York Cancer Project, Vlahov et al. [38] reported that
obesity did not impact CRC screening in blacks, whites, or
Hispanics. These authors did not examine men and women
separately. Leone et al. [34] found that obesity was associated
with lower rates of CRC screening in white women but not
their black counterparts. No studies were identified in the
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Table 3: Prostate-specific antigen testing and weight status.
Study Population/data Source Weight categories1 Findings
Muus et al. 2009, [32]
National face-to-face
survey of American Indian
and Alaskan men in USA
OW, OB, OBI, OBII, OBIII
There was no significant association between receipt of
PSA and OW, OB.
Scales et al. 2007, [9] BRFSS 2002, men ≥40 OW and OB OW was positively associated with PSA testing. OR 1.46
[1.33–1.61].
Fowke et al. 2006,
[10]
In-person interviews, men
from 25 health centers in
USA (85% black)
OW, OBI, OBII, OBIII
OW, OBI, OBII were positively associated with PSA
testing in black men. 1.26 (1.10–1.44), 1.38 (1.18–1.62),
1.37 (1.10–1.72)
OBII was positively associated with PSA testing in white
men. OR 1.67 [1.06–2.63].
There were no other significant associations.
Fontaine et al. 2005,
[11]
BRFSS 2001, men ≥50 OW, OBI, OBII, OBIII
OW, OBI, OBII, and OBIII were positively associated
with PSA testing. OR 1.13 [1.04–1.35], OR 1.26
[1.06–1.36], 1.14 [1.02–1.06].
1Predictors: OW: Overweight, OB: Obese, OBI: Obese I, OBII: Obese II, OBIII: Obese III.
CRC screening literature which examined the relationship of
obesity and screening according to both race and gender.
4. Discussion
The relationship between obesity and cancer screening is
complex. The type of screening test strongly influences this
relationship. In cervical cancer screening, increasing weight
is consistently associated with lower rates of obtaining Pap
smears. In breast cancer screening, there is a less consistent
association between increased weight and decreased mam-
mography. Conversely, prostate cancer screening, measured
by PSA testing, seems to increase as weight increases.
Comparing cervical, breast, and prostate cancer, men seem to
behave opposite of women, suggesting that gender influences
the relationship between screening and weight. However,
CRC screening, the only example of cancer screening which
would allow comparison by gender, does not elucidate the
impact of gender. In fact, the relationship of weight status
and screening in CRC is the least consistent of all the
screening tests. Other variables, such as race, may be an
important source of this inconsistency.
In mammography and Pap smears, race aﬀects the re-
lationship between screening and weight. Increased weight
appears to be more of a barrier in white women in both
mammography and Pap smears. In part, this may be
explained by diﬀerences in perception of weight. Cancer
screening is a behavioral outcome, influenced by personal
factors. Women who see themselves as too heavy are more
likely to feel embarrassment regarding examination [50,
51].White and black women perceive their weight diﬀerently.
White women consider themselves overweight at a lower
BMI, compared to black women [52, 53]. So, white women
may become resistant to screening at a lower BMI. White
women report body dissatisfaction at a lower BMI relative
to their black counterparts [54, 55]. This may create a
“dose-response” eﬀect of obesity and screening behavior with
diﬀerent thresholds for diﬀerent races, at least in women,
which would be consistent with a similar “dose-response”
eﬀect in cancer morbidity and mortality. However, this race
eﬀect in women is not seen in men.
The association of weight status and prostate cancer is
relatively unique in that there appears to be a positive associ-
ation with testing as weight increases, and this eﬀect persists
when men are stratified by race. This may be explained
by diﬀerences in access and utilization of health care. As
weight increases, other comorbid conditions increase, so that
heavier men may be higher utilizers of health care. By having
more encounters with the health care system, these men are
more likely to be counseled or encouraged to be tested.
CRC screening, the only screening which permits the
examination of both race and gender (e.g., white men, white
women, black men, and black women) should elucidate
the combined and often contradictory eﬀects of both race
and gender on cancer screening. However, CRC screening
reveals a confusing pattern of association between weight
status and testing. CRC screening is a more complex test
to study as there are several test choices, and this implicitly
makes for more complicated analyses. Indeed, the literature
varies in outcome reported with most studies reporting
overall screening (stool testing or endoscopy) and some
studies reporting these test options separately. Those studies
which distinguish according to endoscopy and stool testing
suggest that endoscopy, not FOBT, is more likely influenced
by weight status. So, any diﬀerential eﬀects based on race
or gender may be suppressed when examining a composite
variable such as overall CRC screening (endoscopy and stool
blood test).
With the exception of cervical cancer screening, there is
no clear, consistent pattern of association between obesity
and cancer screening. There were no studies of obesity and
cancer screening which examined the combined eﬀect of
race/ethnicity and gender. This is an important gap in the
literature, as finding from this review suggests that screening
behavior across race-gender subgroups, for example, black
men, black women, white men, and white women, is likely to
be very diﬀerent.
Utilization and/or access to health care are important
determinants of cancer screening [34, 41]. However, such
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Table 4: Colorectal cancer screening and weight status.
Study Population/data source
Weight
categories1
Outcome Findings
Chang et al. 2010,
[22]
National Medicare Claims
(Medicare), Veterans
Health Administration
(VHA), ≥65 years old
OW and OB Colorectal cancer screening
There was increased CRC screening in
overweight VHA care recipients OR 1.12
P = 0.002.
There were no other significant
associations between CRC screening and
OB (VHA and Medicare) and OW
Medicare beneficiaries.
Adams-Campbell
et al. 2010, [33]
Black Women’s Health
Study
OW and OB Colonoscopy in past 2 years
There were no significant associations
between colonoscopy and OW, OB.
Leone 2009, [34] NHIS 2005, women only
Collapsed OW
and OB
Colorectal cancer screening
colonoscopy, endoscopy, or
FOBT
OB was negatively associated with CRC
screening in white but not black women.
OR-0.66 P = 0.001.
Muus et al. 2009,
[32]
National face-to-face
survey, American Indian
and Alaskan native men in
USA.
OW, OB, OBI,
OBII, OBIII
FOBT
There were no significant associations
between receipt of FOBT and OW, OB (I,
II, III).
Banerjea et al.
2008, [23]
Medical Expenditure
Survey (MEPS) 2003 and
subset of NHIS (women
only)
OW and OB Colorectal cancer screening
OW was negatively associated with CRC
screening. OR 0.80 [0.66–0.97].
Mitchell et al.
2008, [24]
Canadian Community
Health Survey
OW, OB, OBI,
OBII, OBIII
FOBT
There was no significant association
between receipt of FOBT testing and OW,
OB (I, II, III).
James et al. 2008,
[35]
Wellness for
African-Americans through
Churches (WATCH)
OW, OB, OBI,
OBII, OBIII
FOBT
There was no significant association
between FOBT and OW, or OB (I, II, III)
in men or women.
James et al. 2008,
[35]
WATCH
OW, OB, OBI,
OBII, OBIII
Colorectal cancer screening
There was no significant association
between receipt of overall CRC screening
and OW, or OB (I, II, III) in men or
women.
James et al. 2008,
[35]
WATCH
OW, OB, OBI,
OBII, OBIII
Sigmoidoscopy
There was no significant association
between receipt of sigmoidoscopy and
OW, or OB (I, II, III) for men or women.
James et al. 2008,
[35]
WATCH
OW, OB, OBI,
OBII, OBIII
Past-year CRC screening
There was no significant association
between past-year CRC screening and
OW, or OB (I, II, III) in women or men.
Ferrante et al.
2006, [36]
Medical records of New
Jersey and Pennsylvania
primary care practice
patients ≥50
Collapsed OW
and OB
Colorectal cancer screening
OB was negatively associated with CRC
screening. OR 0.75 P = 0.004.
Menis et al. 2006,
[37]
Maryland Cancer Survey
2002, population-based
random-digit dial
telephone survey
OB and OW Colorectal cancer screening
There was no significant association of
CRC screening with OW or OB.
Vlahov et al. 2005,
[38]
New York Cancer Project OB only Endoscopy
There was no significant association
between obesity and endoscopy.
Heo et al. 2004,
[39]
Behaviorial Risk Factor
Surveillance Survey
(BRFSS) 2001
OW, OB, OBI,
OBII, OBIII
FOBT
There were no significant associations
between BMI category and in men or
women.
Heo et al. 2004,
[39]
BRFSS 2001
OW, OB, OBI,
OBII, OBIII
Sigmoidoscopy
OW and OBII were positively associated
with sigmoidoscopy in last 5 years in
men. OR 1.25 [1.05–1.51], 1.21
[1.03–1.75].
OBI and OBII were negatively associated
with sigmoidoscopy in last 5 years in
women. OR 0.86 [0.78–0.94], OR 0.88
[0.79–0.99].
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Table 4: Continued.
Study Population/data source
Weight
categories1
Outcome Findings
Rosen and
Schneider 2004,
[40]
BRFSS 1999
Morbidly OB
(BMI ≥ 35) Endoscopy
Morbid obesity was negatively associated
with endoscopy in women only. RD − 4.9
[−7.7 to −1.9].
There was no significant association
between morbid obesity and endoscopy
in men.
Rosen and
Schneider 2004,
[40]
BRFSS 1999
Morbidly OB
(BMI ≥ 35) FOBT
Morbid obesity in women only was
negatively associated with FOBT. RD −
3.7 [−7.7 to −1.9].
There was no significant association
between FOBT and morbid obesity in
men.
Rosen and
Schneider 2004,
[40]
BRFSS 1999
Morbidly OB
(BMI ≥ 35) Colorectal cancer screening
Morbid obesity in women only was
negatively associated with overall CRC
screening. RD − 5.6 [−8.5 to −2.6].
There was no association between overall
CRC screening and morbid obesity in
men.
Seeﬀ et al. 2004,
[41]
NHIS 2000 OW and OB Overall CRC
There were no significant associations
between receipt of CRC screening and
OW or OB.
Seeﬀ et al. 2004,
[41]
NHIS 2000 OW and OB FOBT
There was no significant association
between receipt of FOBT and OW or OB.
Seeﬀ et al. 2004,
[41]
NHIS 2000 OW and OB Endoscopy
There was no significant association
between receipt of endoscopy and OW or
OB.
Slattery et al. 2004,
[42]
2 population-based
case-control studies of
colorectal cancer patients,
interviewer-administered
questionnaire
OW and OB Sigmoidoscopy
OW and OB in women were positively
associated with sigmoidoscopy (OR 1.8
and 2.3, resp., P < 0.01).
There was no significant association
between sigmoidoscopy and OW or OB
in men.
Chao et al. 2004,
[43]
Cancer Prevention Study
(CPS) II Nutrition Cohort
1997
OW and OB,
collapsed OBI
and II, morbid
obesity ≥40
Endoscopy
OBI and OBII were negatively associated
with endoscopy in men. OR 0.88
[.82–.94].
OBI and OBII were negatively associated
with endoscopy in women. OR 0.8
[.81–.91].
Morbid obesity in women was negatively
associated with endoscopy. OR 0.71
[0.59–0.85].
1Predictors: OW: Overweight, OB: Obese, OBI: Obese I, OBII: Obese II, OBIII: Obese III.
factors are diﬃcult to measure and control for in small
data sets. So, smaller studies often cannot include these
measures, and this is a particular problem in analyzing racial
subgroups which are likely to be a small subset. Obesity is
more prevalent in minority and underserved groups, who
have less access to health care. Diﬀerent patterns of access
and utilization in weight groups are likely to confound
the relationship of obesity and cancer screening, making
interpretation of the literature even more challenging.
Physician recommendation is an extremely important
determinant of CRC screening [56–64]. However, physicians
often have negative beliefs about obese patients such as
the belief that the patient lacks self-control and that the
patient is unlikely to make recommended behavior changes
[50, 51, 65]. In addition, a patient’s obesity appears to
change the quality of the oﬃce visit. Bertakis and Azari
demonstrated that the qualitative content of a visit is
diﬀerent in obese patients compared to their normal-weight
counterparts [66]. With obese patients, the visit included
less educational time and focused more on technical tasks
such as physical examination. This suggests that doctors
may devote less time and eﬀort in discussions such as
cancer screening. Obese patients, when questioned about
satisfaction with their medical care prior to a new patient
visit, were less satisfied with their medical care compared
to their normal-weight counterparts [66]. This suggests
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a preexisting dissatisfaction which could mean that obese
patients arrive to the physician’s oﬃce less ready to screen.
If obese patients have any particular reluctance to screen
and there is less time devoted to addressing those barriers
or concerns, the likely result would be lower screening. Yet
Ferrante et al. found that lower rates of cancer screening
persist even after controlling for physician recommendation
[12] suggesting that there may be still more to the picture.
There are some obvious diﬀerences in the relationship
between weight and screening in diﬀerent types of screening
tests. Obese women perceive their weight as a barrier
to screening, and these women cite negative attitudes of
providers and inappropriately sized equipment as specific
concerns [26]. These concerns seem more likely to be
activated in the case of cervical cancer screening.
The relationship between obesity and cervical cancer
screening is consistently negative. In contrast, the rela-
tionship between obesity and prostate cancer screening is
generally positive. A blood test such as PSA is relatively
easy to do, whereas cervical cancer screening is invasive and
includes exposure of intimate body parts to a physician with
whom the patient expects to have an ongoing relationship.
So, the invasiveness or embarrassment associated with testing
may be important.
The data review on prostate cancer screening and col-
orectal cancer screening suggests that men may be more
resistant to any barriers presented by obesity. In one of
the studies where there is a positive relationship between
obesity and screening in men, this eﬀect was reduced when
the authors controlled for hypertension and hyperlipidemia
[10]. Perhaps, for men, obesity-related conditions increase
access or exposure to the health care system and, therefore,
obesity facilitates cancer screening in men.
5. Conclusions
Inconsistent methods may be a significant source of variation
in this literature. In fact, two studies examined the same data
set and found diﬀerent outcomes based on such diﬀerent
inclusion/exclusion criteria [14, 25]. More research is needed
to create a comprehensive understanding of obesity and
cancer screening. Specifically, work is needed to examine
obesity and cancer screening in race-gender subgroups such
as white men, white women, black men, and black women,
and such an analysis needs to account for the eﬀects of
the doctor-patient relationship, access to care, and type of
screening test. Regardless of eﬀect on screening, obesity
is clearly associated with increased cancer morbidity and
mortality. So, as obesity becomes increasingly prevalent, it
becomes increasingly important to understand and eliminate
barriers to screening in obese individuals.
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